Perrigo CEO Joseph Papa has cautioned investors against taking up an offer from hostile suitor Mylan. But Papa is already a Mylan shareholder himself.
The Dublin drugmaker’s chief had a stash of 4,965 Mylan shares as of Sept. 11, Bloomberg reports, noting that he nabbed 3,840 of those in mid-March for $221,568.
“We are pleased that Mr. Papa personally saw the upside investment opportunity in Mylan stock when we were trading in the high-$50s, which of course makes his comments now about the company all the more confusing,” Mylan spokeswoman Nina Devlin told the news service.
Since then, though, Mylan’s stock price has taken a hit, and Papa’s March shares–which at one time gained as much as $64,000 in value on buyout interest from Teva ($TEVA)–have turned into a loss, Bloomberg points out. In late July, the Israeli pharma dropped its Mylan plan–opting instead to snatch up Allergan’s ($AGN) generics business–and now those shares are worth about $32,000 less than what Papa paid for them.
Papa hasn’t exactly looked like Mylan’s biggest fan since the Netherlands-based company made its first offer for his company back in April. He’s repeatedly slammed its proposals for undervaluing Perrigo, and he’s taken issue with Mylan’s corporate governance, too.
“Mylan’s pursuit of Perrigo at all costs has … highlighted some very troubling corporate governance values,” he wrote in August in a letter to investors.
Mylan, on the other hand, has remained confident that a majority of Perrigo shareholders will favor its offer, which involves them netting $75 in cash and 2.3 Mylan shares for each Perrigo share.
“We look forward to welcoming (Papa) as a shareholder of the combined Mylan-Perrigo,” Devlin told Bloomberg.
By Carly Helfand
Source: Fierce Pharma
Giovanni Caforio, the former CEO of Bristol Myers Squibb, is set to become the next board chairman of Novartis, which on Tuesday proposed the pharmaceutical industry veteran as its pick to replace Joerg Reinhardt in the role next year. Reinhardt has served as Novartis’ chair since 2013 and plans to retire when his 12-year term ends in 2025.
GE HealthCare has raised the curtain on two ultrasound systems equipped with artificial intelligence programs designed to assist in diagnosing conditions in women’s health, including obstetric exams. The Voluson Signature 20 and 18 imaging systems include AI tools capable of automatically identifying and annotating measurements of fetal anatomy.
Scientists from the University of Edinburgh’s School of Chemistry have revealed a new sustainable method of manufacturing complex molecules that could reduce waste produced during drug production. The method published in Nature Chemistry could help to prevent severe side effects caused by drugs that can exist as enantiomers.
